NUCLIDIUM AG
PrivateLast Round
Series B
Extension
May 27, 2026
Total Funding Raised
$162.63M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
NUCLIDIUM AG is a biotechnology company developing next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Imaging, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NUCLIDIUM AG Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
NUCLIDIUM AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 27, 2026 | ||||
| Series B | Jul 10, 2025 | ||||
| Grant | Jun 27, 2022 | ||||
| Grant | Jan 27, 2022 | ||||
| Series A | Jun 23, 2021 | ||||
Grant | Sep 21, 2020 |
Key People
Founding team and executive leadership
NUCLIDIUM AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| European Innovation Council Fund | Grant |
| Highlight Capital | Series B |
| Neva SGR | Series B, Series B Extension |
| DeepTech & Climate Fonds | Series B, Series B Extension |
| European Investment Bank Group | Series B |
| VIVES Partners | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 27, 2026
$33M round led by Angelini Ventures and Kurma Growth Opportunities Fund.
- Sep 16, 2025
Presenting Phase I/II data for neuroendocrine tumor PET-diagnostic at EANM 2025.
NUCLIDIUM AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NUCLIDIUM AG's valuation, stock price, and market status.